Cariprazine — Vraylar — is the D3-preferring partial agonist. Where aripiprazole and brexpiprazole are partial agonists at D2 with some D3 activity, cariprazine has substantially higher affinity for D3 over D2. D3 receptors are concentrated in limbic regions — the structures involved in motivation, reward, and emotional processing. That regional preference is the theoretical rationale for cariprazine's potential advantages in cognitive symptoms, negative symptoms, motivation, and anhedonia.
- Class
- Third-generation antipsychotic
- Mechanism
- D3 > D2 partial agonist (preferential D3 affinity) + 5-HT1A partial agonist + 5-HT2A antagonism
- Typical dose
- 1.5-6 mg/day
- Half-life
- ~2-4 days (parent); active metabolite ~1-3 weeks
- FDA indications
- Schizophrenia, bipolar I (acute mania, bipolar depression), MDD adjunct
- Key adverse effects
- Akathisia, parkinsonism, somnolence/insomnia, nausea, restlessness, modest metabolic effects
Black box: Increased mortality in elderly patients with dementia-related psychosis
D3 preference is the differentiator — may improve cognitive and negative symptoms more than D2-focused agents. Very long half-life means effects emerge and resolve slowly — both an advantage (missed doses tolerated) and disadvantage (slow titration response).
Whether the theoretical advantage translates into clinically meaningful superiority remains debated. The trial data support efficacy across the indications and suggest modest signal on negative and depressive symptoms, but the clinical experience varies by patient.
FDA approvals are notably broad: schizophrenia, bipolar I (acute mania, bipolar depression), and MDD adjunct. Cariprazine is one of the few SGAs with approval for both bipolar mania and bipolar depression, plus MDD adjunct — broad coverage across mood disorders.
The pharmacokinetics are unusual. The parent drug has a half-life of 2-4 days. The active metabolite has a half-life of 1-3 weeks. The combined effect is very long persistence — slow on, slow off. Once-daily dosing produces smooth steady-state. Missed doses are buffered. But it also means switching to or from cariprazine takes weeks. Side effects that emerge from a dose change resolve slowly. Plan transitions carefully.
Akathisia, parkinsonism, somnolence, and modest weight gain are the main side effects. Metabolic burden is favorable — less than quetiapine or olanzapine, comparable to lurasidone and aripiprazole.
Cariprazine is a third-generation antipsychotic whose D3-receptor preference is theorized to give it a pro-motivational, anti-anhedonic character.
Mechanism note: Cariprazine's D3 preference and broad mood indications make it attractive for negative-symptom and bipolar-depression presentations; the very long half-life demands patient titration.
For bipolar depression in particular, cariprazine has earned a place in the consideration set alongside quetiapine and lurasidone. The choice often comes down to side effect tolerability and cost.
- Cost
- Brand-only Vraylar: ~$1,500/month.
- Generic status
- No generic anticipated near-term.
- Formulary typical
- Specialty tier with PA universal.
- Access friction
- PA documenting prior agents typical. AbbVie co-pay program for commercial patients.
Prescriber tip: For bipolar depression, PA often approves after documented lurasidone or quetiapine trial. Long half-life means missed doses tolerated — but switching requires substantial washout planning.